Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 3:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 862 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Attention Deficit/Hyperactivity Disorder Clear all
Not yet recruiting Phase 1Phase 2 Interventional

A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep

NCT07061470
View directory record Official record
Conditions
ADHD, Sleep Problems
Interventions
Ferrous Sulfate, Placebo
Dietary Supplement · Other
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
8 Years to 18 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 26, 2026, 3:59 AM EDT
Active, not recruiting Not applicable Interventional

Rapid Entrainment and Signal-guided Neuromodulation for Behavioral Health

NCT07812987
View directory record Official record
Conditions
Anxiety, PTSD, ADHD, Depression Disorders, Post-traumatic Stress, Substance Use, Executive Function, Sleep Disturbance
Interventions
AIP-Informed Integrative Psychotherapy, Transcutaneous Auricular Vagus Nerve Stimulation, Regulated Breathing and Autonomic Regulation, Audiovisual Entrainment, Vibroacoustic Stimulation, Breathwork-Based Auditory Driving Entropy Module (BADEM), Transcranial Electrical Stimulation
Behavioral · Device
Lead sponsor
Tactical Mind Research Coalition, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 26, 2026, 3:59 AM EDT
Recruiting Phase 4 Interventional

Predictors of Improvements in Irritability and Aggression in Children With ADHD Treated With CNS Stimulants

NCT06871488
View directory record Official record
Conditions
ADHD - Attention Deficit Disorder With Hyperactivity, Irritability, Aggression Childhood
Interventions
CNS Stimulant, Placebo, CNS Stimulant open label first phase
Drug · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
7 Years to 12 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 26, 2026, 3:59 AM EDT
Completed Phase 4 Interventional Results available

Omega-3 Supplementation to ADHD Medication in Children

NCT02204410
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Deficient Emotional Self-Regulation
Interventions
Omega-3 Fatty Acid, ADHD Medication
Dietary Supplement · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2017 · Synced Oct 26, 2026, 3:59 AM EDT
Completed Not applicable Interventional

Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders

NCT00025779
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Autistic Disorder, Pervasive Development Disorders
Interventions
methylphenidate, guanfacine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
5 Years to 14 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2009 · Synced Oct 26, 2026, 3:59 AM EDT
Terminated Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.

NCT02163915
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
TAK-137, TAK-137 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Marlton, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 26, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia

NCT00857220
View directory record Official record
Conditions
Insomnia, Attention Deficit Hyperactivity Disorder
Interventions
eszopiclone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
89
States / cities
Tucson, Arizona • Little Rock, Arkansas • Carson, California + 70 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 26, 2026, 3:59 AM EDT
Not listed Phase 4 Interventional

Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)

NCT00794625
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Valproate, Risperidone, Placebo, Stimulant medication, Behavioral family counseling
Drug · Behavioral
Lead sponsor
Joseph Blader
NIH
Eligibility
6 Years to 12 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Glen Oaks, New York • Stony Brook, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 26, 2026, 3:59 AM EDT
Completed Not applicable Interventional Results available

Trigeminal Nerve Stimulation for ADHD

NCT02155608
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Active eTNS, Sham eTNS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
8 Years to 12 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 26, 2026, 3:59 AM EDT
Completed Not applicable Interventional Results available

Cognitive Training Trial

NCT01133418
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Computerized Progressive Attention Training, Sham Comparator Cognitive Training
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 12 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 26, 2026, 3:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Novel Measure of Social Deficits in Children

NCT02035176
View directory record Official record
Conditions
Autism Spectrum Disorders, ADHD
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
6 Years to 11 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 26, 2026, 3:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuroimaging of Smokers With and Without Attention Deficit Hyperactivity Disorder (ADHD)

NCT01123668
View directory record Official record
Conditions
Smoking, ADHD
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 26, 2026, 3:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Initial Validation of the Vanderbilt ADHD Measure for Adolescent Patients in the ICISS Project

NCT01964209
View directory record Official record
Conditions
ADHD
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 26, 2026, 3:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Multi-Family Group Therapy for Reducing Behavioral Difficulties in Youth

NCT00404911
View directory record Official record
Conditions
Oppositional Defiant Disorder, Conduct Disorder
Interventions
MFG therapy, Standard of Care
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
7 Years and older
Enrollment
416 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Oct 26, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

NCT03834766
View directory record Official record
Conditions
ADHD
Interventions
AMPH ER Tab 5, 10, 15 and 20 mg, AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 26, 2026, 3:59 AM EDT
Completed Phase 1 Interventional

Mental Health Services for Foster and Adopted Children

NCT00056303
View directory record Official record
Conditions
Problem Behaviors, Attention Deficit Hyperactivity Disorder, Depression
Interventions
Attachment and Biobehavioral Catch-up, Developmental Education for Families
Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
20 Months to 36 Months
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 26, 2026, 3:59 AM EDT
Completed Phase 2 Interventional

Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3

NCT00015054
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 1999
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 26, 2026, 3:59 AM EDT
Completed Phase 4 Interventional Results available

Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation

NCT01924429
View directory record Official record
Conditions
ADHD
Interventions
Lisdexamfetamine
Drug
Lead sponsor
Jeffrey Newcorn
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 26, 2026, 3:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tantrum Tamers 2.0: The Role of Emotion

NCT03597789
View directory record Official record
Conditions
Child Behavior, Attention Deficit and Disruptive Behavior Disorders, Problem Behavior
Interventions
Helping the Noncompliant Child (HNC)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 8 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 26, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Results available

Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI

NCT02225106
View directory record Official record
Conditions
Cognition Disorder, Attention Deficit Disorder, Traumatic Brain Injury
Interventions
Methylphenidate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 26, 2026, 3:59 AM EDT
Terminated Phase 4 Interventional

Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL

NCT00299234
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine
Drug
Lead sponsor
Monarch Medical Research
Other
Eligibility
6 Years to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Oct 26, 2026, 3:59 AM EDT
Completed Phase 3 Interventional

Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment

NCT00343811
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
23
States / cities
Little Rock, Arkansas • Irvine, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 26, 2026, 3:59 AM EDT
Not listed Phase 3 Interventional

Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy

NCT01330693
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine, Sugar Pill
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
7 Years to 12 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 26, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

NCT03605680
View directory record Official record
Conditions
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Centanafadine SR, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 26, 2026, 3:59 AM EDT